PharmD – Legal Intern, Law Office of Albert Wai-Kit Chan, PLLC
Dr. Kevin Chen earned a Doctor of Pharmacy (Pharm.D.) degree from Rutgers University in 2014. He worked as a pharmacist at a leading pharmacy retail chain for 3 years before attending law school. He is set to earn a Juris Doctor (J.D.) degree from New York Law School in 2020. Currently, he is a legal intern at the Law Offices of Albert Wai-Kit Chan, PLLC.
Chair Professor, Institute of Interdisciplinary Sciences, Peking University
Prof. Dongmin Chen is a chair professor at the Institute of Interdisciplinary Sciences at Peking University. He has developed and taught four Entrepreneurship courses at Peking University since 2012. He leads the planning committee for the university innovation ecosystem development and innovation and entrepreneurship education program. He was the former Director of the Office of Science and Technology Development at Peking University, which oversees university technology licensing, spin-offs, several incubators and investment funds. He is a serial entrepreneur and has co-founded two silicon-valley- startups.
Dr. Chen was a former Sr. Rowland Fellow at Harvard University for 15 years and a serial entrepreneur and co-founder of two Silicon Valley companies. Prof. Chen is the International Adviser of WIPO Global Innovation Index and the Honorary Advisor and former Chairman & President of Chinese American Semiconductor Professional Association. Prof. Chen is an Associate Editor of Applied Physics letter. His research expertise includes nanotechnologies, RRAM, MEMS-CMOS integration; wearable sensor, artificial intelligence, and blockchain technologies. He co-authored more than 100 scientific publications and 150 US and international patents.
Senior Partner, Bright Spot Management Consultants Corp., China/ Taiwan/Hong Kong
Dr. Keith Chan is a pharmaceutical scientist, a regulator, a professor, and an entrepreneur. He obtained his Ph.D. degree in Pharmaceutics from the University of Minnesota. He is currently Senior Advisor of Cornerstone IP Foundation and Adjunct Professor at the Graduate Institute of Intellectual Property and Technology Management, College of Commerce, National Chengchi University at Taiwan. He is also a Senior Partner at the Bright Spot Management Consultants Corp based on China, Hong Kong, and Taiwan. He is Senior Research Fellow at the Institute of International Intellectual Property at Beijing University Law School. He also serves as Director of International Affairs, GloboAsia LLC, Rockville, MD, USA and as advisors for several research institutes and regulatory agencies in Asia, as well as consultants for various pharmaceutical firms in Asia and in the US.
Dr. Chan worked for Ciba-Geigy Corporation (now Novartis) in Ardsley, New York for 15 years and held various senior and management positions. He published >150 abstracts/research articles in peer-reviewed journals and >200 professional presentations. He was elected fellow of the American Association of Pharmaceutical Scientists (AAPS) in 1995 for his scientific accomplishments on drug absorption in humans. He also worked for the US FDA as Division Director at the Office of Generic Drugs. In 1997, he co-foundered GloboMax LLC, a drug development organization, in Hanover, Maryland in 1997 and served as a consultant for numerous multi-national pharmaceutical and biotech firms in the US, Europe, and Asia. GloboMax was acquired by ICON, plc in 2003 and Dr. Chan exited from the operation. He served as Professor and Adjunct Professor at the School of Pharmacy, University of Maryland at Baltimore for many years and also served as Adjunct Professor and National Board of Advisor, College of Pharmacy, the University of Minnesota since 1984. He also taught in Asia including National Defense Medical Center, National Yang Ming University in Taiwan and Shang Yang Pharmaceutical University in China.
Over the last 15 years, he assisted various Asian companies, organized numerous workshops and conferences in China, Taiwan, Hong Kong, Singapore, and Korea. He lectured frequently in Asia in the hope of upgrading their pharmaceutical industry. He had success in assisting several Asian companies in their technology transfers and licensing. He also managed those new drug development projects starting from IND up to NDA. Some of those drug candidates have now marketed and launched in Japan, the United States, Asia, and Europe. His new adventure is joining a professional strategy consulting firm to provide various financial and investment networks to those technology companies to strengthen their financial structure that leads to products development or market expansion.
Founder and Director of USCIPI
Dr. Albert Wai-Kit Chan is the Managing Partner of the Law Offices of Albert Wai-Kit Chan, PLLC. He is
a former research scientist who forged his legal career by combining his training as a molecular biologist with the emerging legal needs of the biotechnology industry in the late 1980s. Dr. Chan handles all areas of intellectual property law (including technology transfer, patents, trademarks, copyrights, business transactions, and trade secrets), and his specialty is biotechnology patents. He is well-versed in all aspects of prosecution and litigation and is experienced in licensing, technology transfer and the ALBERT WAI-KIT CHAN, PH.D., J.D. Biographical Information evaluation of intellectual property portfolios. Dr. Chan works extensively with both U.S. and international companies. He has helped scores of scientists and inventors obtain the intellectual property protection they need to be competitive in their fields. His clients range from individual inventors to upand-coming companies to well-established prestigious research institutes.
Dr. Chan has been frequently involved in transactional work in China, which includes facilitating joint ventures and contracts between East and West companies and building up clients’ intellectual property portfolios. For those clients looking to expand their business in China, he has not only provided patent procurement services but also, equally important, patent enforcement. He has performed analysis and evaluation of clients’ intellectual property to determine the scope and securement of the protection of their intellectual property.
From 1996 through 2013, Dr. Chan taught as an adjunct professor of law at The City University of New York School of Law. His classes included intellectual property law, patent law, technology transfer, Internet and the law, food and drug law, and international business law. He is currently adjunct associate professor in the School of Life Sciences at The Chinese University of Hong Kong and has adjunct professorship in the Department of Health Technology and Informatics at The Hong Kong Polytechnic University. Dr. Chan is active in a number of legal organizations including, among others, United States-China Intellectual Property Institute, Inc. (a New York Not-For-Profit Corporation) where he is founder and director.
Dr. Chan received his J.D. degree from Columbia University School of Law in New York. He was awarded his Ph.D. in virology at Baylor College of Medicine in Houston, Texas, and he completed his postdoctoral training at Cold Spring Harbor Laboratory in New York as an American Cancer Society postdoctoral fellow. Dr. Chan is a graduate of The Chinese University of Hong Kong, and he was born and raised in Hong Kong. Dr. Chan is currently a registered foreign lawyer at the Law Offices of Hui & Lam in Hong Kong. Hui & Lam is now in association with Long An Law Firm, a full service law firm headquartered in Beijing, China.
International Business Development, US and European Patent Attorney at Berggren Oy (Helsinki, Finland)
Dr. Robert Alderson is one of a very small number of intellectual property attorneys working at a European IP firm who has a law degree from the United States and is qualified to practice before both the United States Patent and Trademark Office and the European Patent Office. Prior to moving to Europe nearly 8 years ago, he worked in New York as an intellectual property attorney for 14 years, including over 10 years in the IP group of an AmLaw 100 law firm.
His responsibility at Berggren primarily involves international business development activities. In such capacity Robert often writes and speaks on a variety of intellectual property-related topics, particularly concerning comparative IP law issues. In his professional capacity, Robert has a great deal of experience in patent prosecution, litigation, licensing, opinion letter-writing, and IP due diligence matters.
